Clinical Trials Browser

relatlimab × Gastrointestinal × Clear all

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03044613 2026-03-23

Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer

Phase 1 Active not recruiting

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT05176483 2026-03-12

STELLAR-002

Phase 1 Recruiting

GastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT03026140 2026-03-05

NICHE

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT07369791 2026-01-28

NOBLE

Phase 2 Not yet recruiting

Gastrointestinal

Advanced Biliary Tract Cancer(BTC)

NCT05337137 2026-01-12

RELATIVITY-106

Phase 1/2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04567615 2026-01-08

A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

Phase 2 Completed

266 enrolled 28 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03610711 2025-12-22

REACTION

Phase 1/2 Active not recruiting

Gastrointestinal

Gastroesophageal Cancer

NCT04658147 2025-12-18

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

Phase 1 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02060188 2025-11-06

CheckMate142

Phase 2 Completed

385 enrolled 17 charts 4 FDA

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT03642067 2025-06-15

Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

Phase 2 Completed

59 enrolled 11 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT03867799 2024-06-14

iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04062656 2024-03-12

IMAGINE

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT02935634 2023-06-09

FRACTION-GC

Phase 2 Completed

190 enrolled 25 charts

Gastrointestinal

Advanced Gastric Cancer

NCT03704077 2020-05-19

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Stomach Neoplasms